Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - canine distemper virus (lederle strain), canine parvovirus (cpv 780916 strain), canine adenovirus type 2 (manhattan strain), canine parainfluenza (manhattan strain) - lyophilisate and solvent for suspension for injection - per cent - canine distemper virus vaccine + canine adenovirus vaccine + canine parvovirus vaccine + canine para - canine - immunological - live vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

merial animal health limited - canine distemper virus, live, canine adenovirus type 2, live, canine parvovirus, live, canine parainfluenza virus, live - lyophilisate and solvent for solution for injection - unknown - canine distemper virus vaccine + canine adenovirus vaccine + canine parvovirus vaccine + canine para - canine - immunological - live vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - canine parvovirus, live - lyophilisate and solvent for suspension for injection - unknown - canine parvovirus vaccine - canine - immunological - live vaccine

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b and canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated) - immunologicals for canidae, live viral vaccines - dogs - active immunisation of dogs from six weeks of age.to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus,to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - canine parainfluenza type-2 virus, strain cpiv-2 bio 15 (live attenuated) - immunologicals for canidae, live viral vaccines - dogs - active immunisation of dogs from six weeks of age to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa. - canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090 and l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - immunologicals for canidae, live viral and inactivated bacterial vaccines - dogs - active immunisation of dogs from six weeks of age. - to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus, - to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 3 weeks after completion of the primary course for cpiv and from 4 weeks after completion of the primary course for leptospira components. duration of immunity: at least one year following the primary vaccination course for all components of versican plus pi/l4.

European Union - English - EMA (European Medicines Agency)

zoetis belgium s.a. - canine parainfluenza virus, leptospira and rabies virus. - immunologicals for canidae, live and inactivated viral and bacterial vaccines - dogs - active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - canine parvovirus (cpv) immunoglobulins (vet.) - suspension for injection (im/sc/iv) - formulation: each 1 ml contains: canine parvovirus (cpv t-86 strain) ............. >1024 hiu titer hiu - hemagglutination-inhibition unit

Philippines - English - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - canine distemper virus immunoglobulins (vet.) - suspension for injection (im/sc/v) - formulation: each 1 ml contains: canine distemper virus immunoglobulins (onderstepoort strain)............ > 320 vnab50 vnab - virus neutralizing antibody

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.